Full Press Release Details
Eidos Therapeutics Announces Positive Phase 2 Data For AG10 In Symptomatic Patients With Mutant Or Wild-type TTR Amyloid Cardiomyopathy.
BBIO
Eidos Therapeutics Announces Positive Phase 2 Data For AG10 In Symptomatic Patients With Mutant Or Wild-type TTR Amyloid Cardiomyopathy
Key Takeaway: Eidos Therapeutics Announces Positive Phase 2 Data For AG10 In Symptomatic Patients With Mutant Or Wild-type TTR Amyloid Cardiomyopathy
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis